Status: Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: Apr 2, 2025Locations: 1
Eligibility criteria
Age, 18-65 years old (inclusive), weight >=45kg, male and female; [+4]
Use of rituximab or other monoclonal antibodies within 1.6 months. [+7]